Company intelligence / Profile preview
NiKang Therapeutics
Wilmington, Delaware, United Statesnikangtx.com ↗
- Ownership
- Private
- Employees
- ~42
- Development stage
- Phase 2
01
Overview
NiKang has three programs in clinical trials: NKT2152 (HIF2α inhibitor) in Phase 1b/2 for hepatocellular carcinoma and clear cell renal cell carcinoma, NKT3447 (CDK2 inhibitor), and NKT3964 (CDK2 degrader) which completed first cohort dosing in Phase 1 in March 2025.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on NiKang Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NiKang Therapeutics.